ézétimibe (Ezetrol®) chez le patient diabétique

Scheen, André; Radermecker, Régis

Download

Article (Scientific journals)

ézétimibe (Ezetrol®) chez le patient diabétique

Scheen, André; Radermecker, Régis

2009 • In Revue Médicale de Liège, 64 (12), p. 606-611

Peer reviewed

Permalink
https://hdl.handle.net/2268/29559

PubMed
20143743

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

200912_02.pdf

Publisher postprint (477.74 kB)

Download

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Cardiovascular disease; Statin; Ezetimibe; Diabetes; Cholesterol

Abstract :

[fr] L’ézétimibe (Ezetrol®) inhibe sélectivement l’absorption intestinale du cholestérol et des phytostérols apparentés. Son mécanisme d’action résulte en un effet hypocholestérolémiant synergique en combinaison avec une statine, inhibant la synthèse hépatique de cholestérol, ce qui a conduit à la commercialisation d’une combinaison fixe ézétimibe-simvastatine (Inegy®). L’ézétimibe a été plus spécifiquement étudié chez les personnes avec un diabète de type 2 qui sont confrontées à un risque cardio-vasculaire particulièrement élevé. Le but de cet article est de présenter les avancées et les particularités en ce qui concerne l’utilisation de l’ézétimibe dans la population diabétique de type 2.

Disciplines :

Pharmacy, pharmacology & toxicology
Endocrinology, metabolism & nutrition

Author, co-author :

Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale

Radermecker, Régis ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques

Language :

French

Title :

ézétimibe (Ezetrol®) chez le patient diabétique

Alternative titles :

[en] Ezetimibe (Ezetrol®) in patients with diabetes

Publication date :

December 2009

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Hopital de Baviere, Liège, Belgium

Volume :

Issue :

Pages :

606-611

Peer reviewed :

Peer reviewed

Additional URL :

http://www.rmlg.ulg.ac.be

Available on ORBi :

since 15 February 2010

Statistics

Number of views

204 (2 by ULiège)

Number of downloads

1212 (3 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

Bibliography

Paquot N, Scheen AJ.- Prévention cardio-vasculaire chez le patient diabétique de type 2. Rev Med Liège, 2003, 58, 271-274.
DeBacker G, Ambrosioni E, Borch-Johnsen K, et al.- Executive Summary. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on cardiovascular disease prevention in clinical practice. Eur Heart J, 2003, 24, 1600-1609.
Ryden L, Standl E, Bartnik M, et al.- Guidelines on diabetes, pre-diabetes, and cardiovascular diseases : executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J, 2007, 28, 88-136.
Fruchart JC, Sacks F, Hermans MP, et al.- The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol, 2008, 102 (10 Suppl), 1K-34K
et Diab Vasc Dis Res, 2008, 5, 319-335.
Scheen AJ, Radermecker R, De Flines J, Ducobu J.- Actualités thérapeutiques en lipidologie. Rev Med Liège, 2007, 62, 324-328.
Davidson MH.- Combination lipid-lowering therapy in diabetes. Curr Diab Rep, 2003, 3, 263-268.
Worz CR, Bottorff M.- Treating dyslipidemic patients with lipid-modifying and combination therapies. Pharmacotherapy, 2003, 23, 625-637.
Tenenbaum A, Fisman EZ, Motro M, Adler Y.- Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes : therapeutic options beyond statins. Cardiovasc Diabetol, 2006, 5, 20.
Ducobu J, Scheen AJ, Legat P, et al.- Place des fibrates dans le traitement de patients avec une dyslipidémie athérogène. Rev Med Liège, 2009, 64, 512-518.
Belsey J, de Lusignan S, van Vlymen J, et al.- Reducing coronary risk by raising HDL-cholesterol: risk modelling the addition of nicotinic acid to existing therapy. Curr Med Res Opin, 2008, 24, 2703-2709.
Neal RC, Jones PH.- Complementary therapy to target LDL cholesterol : the role of the ezetimibe/simvastatin combination. Vasc Health Risk Manag, 2006, 2, 31-38.
Scheen AJ.- Ezétimibe (Ezetrol® ). Rev Med Liège, 2004, 59, 246-250.
Scheen AJ, Radermecker RP.- Combinaison fixe ézétimibe- simvastatine (Inegy® ). Rev Med Liège, 2007, 62, 585-590.
Altmann SW, Davis HR, Zhu L, et al.- Niemann-Pick C1 like protein is critical for intestinal cholesterol absorption. Science, 2004, 303, 1201-1204.
Radermecker RP, Scheen AJ.- Distinction entre patients bons synthétiseurs et bons absorbeurs pour optimiser le traitement hypocholestérolémiant. Rev Med Suisse, 2006, 2, 1910-1915.
Jakulj L, Vissers MN, Groen AK, et al.- Baseline cholesterol absorption and the response to ezetimibe/simvastatin therapy; a post-hoc analysis of the ENHANCE trial. J Lipid Res, 2009, Oct 14 [Epub ahead of print].
van Himbergen TM, Matthan NR, Resteghini NA, et al. - Comparison of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis and absorption markers. J Lipid Res, 2009, 50, 730-739.
Lally S, Tan CY, Owens D, Tomkin GH.- Messenger RNA levels of genes involved in dysregulation of postprandial lipoproteins in type 2 diabetes: the role of Niemann-Pick C1-like 1, ATP-binding cassette, transporters G5 and G8, and of microsomal triglyceride transfer protein. Diabetologia, 2006, 49, 1008-1016.
Ravid Z, Bendayan N, Delvin E, et al.- Modulation of intestinal cholesterol absorption by high glucose levels: impact on cholesterol transporters, regulatory enzymes, and transcription factors. Am J Physiol Gastrointest Liver Physiol, 2008, 295, G873-885.
Gylling H, Miettinen TA.- Cholesterol absorption : influence of body weight and the role of plant sterols. Curr Atherosclerosis Rep, 2005, 7, 466-471.
Steinmetz A.- Lipid-lowering therapy in patients with type 2 diabetes : the case for early intervention. Diabetes Metab Res Rev, 2008, 24, 286-293.
Tomkin GH.- Targets for intervention in dyslipidemia in diabetes. Diabetes Care, 2008, 31, S241-S248.
Stroup JS, Kane MP, Busch RS.- The antilipidemic effects of ezetimibe in patients with diabetes. Diabetes Care, 2003, 26, 2958-2959.
Simons L, Tonkon M, Masana L, et al.- Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome. Curr Med Res Opin, 2004, 20, 1437-1445.
Goldberg RB, Guyton JR, Mazzone T, et al.- Ezetimibe/simvastatin vs atorvastatin in patients with Type 2 diabetes mellitus and hypercholesterolemia : the VYTAL Study. Mayo Clin Proc, 2006, 81, 1579-1588.
Denke M, Pearson T, McBride P, et al.- Ezetimibe added to ongoing statin therapy improves LDL-C goal attainment and lipid profile in patients with diabetes or metabolic syndrome. Diab Vasc Dis Res, 2006, 3, 93-102.
Constance C, Westphal S, Chung N, et al.- Efficacy of ezetimibe/simvastatin 10/20 and 10/40 mg compared with atorvastatin 20 mg in patients with type 2 diabetes mellitus. Diabetes Obes Metab, 2007, 9, 575-584.
Gaudiani ML, Lewin A, Meneghini L, et al.- Efficacy and safety of ezetimibe co-administered with simvastatin in thiazolidinedione-treated type 2 diabetic patients. Diabetes Obes Metab, 2005, 7, 88-97.
Hildemann SK, Barho C, Karmann B, et al.- Dual cholesterol inhibition with ezetimibe/simvastatin in pre-treated hypercholesterolaemic patients with coronary heart disease or diabetes mellitus: prospective observational cohort studies in clinical practice. Curr Med Res Opin, 2007, 23, 713-719.
Farnier M, Averna M, Missault L, et al.- Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study. Int J Clin Pract, 2009, 63, 547-559.
Vaverkova H, Farnier M, Averna M, et al.- Lipid-altering efficacy of ezetimibe-simvastatin 10/20 mg compared to rosuvastatin 10 mg in high-risk patients with and without type 2 diabetes (abstract). Diabetologia, 2009, 52, S279.
Gazi IF, Tsimihodimos V, Tselepis AD, et al.- Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles. Expert Opin Biol Ther, 2007, 7, 53-72.
Rizzo M, Rini GB, Berneis K.- Effects of statins, fibrates, rosuvastatin, and ezetimibe beyond cholesterol: the modulation of LDL size and subclasses in high-risk patients. Adv Ther, 2007, 24, 575-582.
Rizzo M, Rini GB, Berneis K.- The clinical relevance of LDL size and subclasses modulation in patients with type-2 diabetes. Exp Clin Endocrinol Diabetes, 2007, 115, 477-482.
Tomassini JE, Mazzone T, Goldberg RB, et al.- Effect of ezetimibe/simvastatin compared with atorvastatin on lipoprotein subclasses in patients with type 2 diabetes and hypercholesterolaemia. Diabetes Obes Metab, 2009, 11, 855-864.
Pastromas S, Terzi AB, Tousoulis D, Koulouris S.- Postprandial lipemia: an under-recognized atherogenic factor in patients with diabetes mellitus. Int J Cardiol, 2008, 126, 3-12.
Radermecker RP, Scheen AJ.- Serum plant sterols and atherosclerosis: is there a place for statin-ezetimibe combination? J Am Coll Cardiol, 2006, 47, 1496-1497.
Lally SE, Owens D, Tomkin GH.- Sitosterol and cholesterol in chylomicrons of type 2 diabetic and non-diabetic subjects: the relationship with ATP binding cassette proteins G5 and G8 and Niemann-Pick C1-like 1 mRNA. Diabetologia, 2007, 50, 217-219.
Howard BV, Roman MJ, Devereux RB, et al.- Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial. JAMA, 2008, 299, 1678-1689.
Fleg JL, Mete M, Howard BV, et al.- Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. J Am Coll Cardiol, 2008, 52, 2198-2205.
Cannon CP, Giugliano RP, Blazing MA, et al.- Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J, 2008, 156, 826-832.
Califf RM, Harrington RA, Blazing MA.- Premature release of data from clinical trials of ezetimibe. N Engl J Med, 2009, 361, 712-717.
Derosa G, D'Angelo A, Franzetti IG, et al.- Efficacy and safety of ezetimibe/simvastatin association on nondiabetic and diabetic patients with polygenic hypercholesterolemia or combined hyperlipidemia and previously intolerant to standard statin treatment. J Clin Pharm Ther, 2009, 34, 267-276.
Kanat M, Serin E, Tunckale A, et al.- Multi-center, open label, crossover designed prospective study evaluating the effects of lipid lowering treatment on steroid synthesis in patients with type 2 diabetes (MODEST Study). J Endocrinol Invest, 2009, Sept 11 [Epub ahead of print].
Florentin M, Liberopoulos EN, Elisaf MS.- Ezetimibe-associated adverse effects : what the clinician needs to know. Int J Cardiol, 2008, 62, 88-96.
Ara R, Tumur I, Pandor A, et al.- Ezetimibe for the treatment of hypercholesterolaemia: a systematic review and economic evaluation. Health Technol Asess, 2008, 12, 1-212.